Table 1 Baseline characteristics of the studies included in this meta-analysis
From: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma
Study | Country | Sample size | Mean age (years) | Men/women | Disease status | Stages | Intervention | Chemotherapy regimen | Study quality |
|---|---|---|---|---|---|---|---|---|---|
Coiffier 2002 [22] | Multiple countries | 399 | 69.0 | 199/200 | Previously untreated DLBCL | I-IV | Rituximab (375 mg per square meter, on day 1 of each of the eight cycles of CHOP) | CHOP | 4 |
Habermann 2006 [23] | Multiple countries | 546 | 69.5 | 273/273 | Previously untreated DLBCL | I-IV | Rituximab (375 mg per square meter, 7 and 3 days before cycle 1, and 2 days before cycles 3, 5, and, if administered, 7) | CHOP | 3 |
Pfreundschuh 2006 [24] | Multiple countries | 823 | 47.0 | 478/345 | Good-prognosis DLBCL | I-IV | Rituximab (375 mg per square meter given IV on days 1, 22, 43, 64, 85, and 106 of the chemotherapy regimen) | CHOP | 4 |
Avilés 2007 [25] | Mexico | 196 | 59.8 | 105/91 | High-risk DLBCL | III-IV | Rituximab (375 mg per square meter) | CEOP | 2 |
Vellenga 2008 [26] | The Netherlands | 225 | 54.5 | 130/95 | Relapsed/progressive DLBCL | I-IV | Rituximab (375 mg per square meter was administered on day 5 of the DHAP course or on day 6 of the VIM course) | DHAP | 1 |
Pfreundschuh 2008 [27] | Germany | 1222 | 68.3 | 650/572 | Previously untreated DLBCL | I-IV | Bi-weekly dosing of rituximab (375 mg per square meter) | CHOP | 4 |
Avilés 2010 [28] | Mexico | 100 | 50.2 | 48/52 | Refractory DLBCL | III-IV | Rituximab (375 mg per square meter day 1 IV every cycle) | ESHAP | 1 |
Vose 2013 [29] | US | 224 | 57.7 | 142/82 | Relapsed DLBCL | NA | Rituximab (375 mg per square meter on days 19 and 12) or I-tositumomab (dosimetric dose of 5 mCi on day 19 and therapeutic total-body dose of 0.75 Gy on day 12) | BEAM | 4 |
Ketterer 2013 [30] | France | 222 | 49.2 | 139/83 | Localized low-risk DLBCL | I-II | Rituximab (375 mg per square meter was administered on days 1, 15, 29, and 43 of the regimen) | ACVBP | 3 |
Seymour 2014 [31] | Multiple countries | 787 | 61.0 | 387/400 | Previously untreated DLBCL | I-III | Bevacizumab (10 mg kg−1 q2w or 15 mg kg− 1 q3w) | R-CHOP | 2 |
Offner 2015 [32] | Multiple countries | 164 | 59.0 | 88/76 | Previously untreated DLBCL | I-IV | Bortezomib 1.3 mg per square meter by IV on days 1, 4, 8, and 11 | R-CHOP | 3 |
Fayad 2015 [33] | US | 151 | 59.0 | 85/66 | Relapsed DLBCL | I-IV | Dacetuzumab administered on days 1, 3, 8, and 15 | R-ICE | 3 |
Hu 2017 [34] | China | 144 | 49.4 | 98/46 | DLBCL | NA | Rituximab (375 mg per square meter was administered every 2 months for 1 year) | CHOP | 2 |
van Imhoff 2017 [35] | Multiple countries | 445 | 57.0 | 272/173 | Relapsed or Refractory DLBCL | I-IV | Ofatumumab 1000 mg or rituximab 375 mg per square meter was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP) | DHAP | 3 |
Vitolo 2017 [36] | Multiple countries | 1418 | 62.0 | 752/666 | Previously untreated advanced-stage DLBCL | I-IV | Obinutuzumab (1000 mg IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycles 2 to 8) or rituximab (375 mg per square meter IV on day 1 of cycles 1 to 8) | CHOP | 4 |
Czuczman 2017 [37] | Multiple countries | 102 | 67.0 | 61/41 | Relapsed or Refractory DLBCL | NA | lenalidomide (25 mg per day, 21 days of 28-day cycle) or rituximab (375 mg per square meter IV on days 1, 8, 15, and 22 of cycles 1 to 8) | GEO | 2 |
Leonard 2017 [38] | Multiple countries | 201 | 63.0 | 107/94 | Previously untreated DLBCL | I-IV | Bortezomib 1.3 mg per square meter IV on days 1 and 4 | R-CHOP | 3 |
Younes 2009 [39] | Multiple countries | 838 | 62.0 | 447/391 | Previously untreated non-GCB DLBCL | I-IV | Ibrutinib (560 mg per day orally) | R-CHOP | 4 |